NK Insights: An Interactive Corneal Sensitivity Testing Workshop

Thanks for your interest in this podcast. Please read this important program information before listening.

Episode Description

In this podcast, experts John D. Gelles, OD, FAAO, FIAOMC, FCLSA, FSLS, FBCLA; and John Hovanesian, MD, FACS; discuss the importance of comprehensive strategies when performing corneal sensitivity testing in patients suspected of having neurotrophic keratitis (NK).

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Summarize the importance of a timely and accurate diagnosis of neurotrophic keratitis
• Integrate corneal sensitivity testing into the assessment of ocular surface disease

Acknowledgment of Educational Grant Support

This activity is supported by an educational grant from Dompé US, Inc; and Brill Engines.

Chair:

John D. Gelles, OD, FAAO, FIAOMC, FCLSA, FSLS, FBCLA

Director, Specialty Contact Lens Division
Cornea and Laser Eye Institute
CLEI Center for Keratoconus
Assistant Clinical Professor, Department of Ophthalmology
Rutgers New Jersey Medical School
Adjunct Clinical Professor, New England College of Optometry
State University of New York College of Optometry
Illinois College of Optometry
Teaneck, NJ

Disclosures: Research/Consultant: CorneaGen, OSI, Ovitz, UltraVision; Consultant: Corza Medical, Essiri; Speaker: Glaukos, Oculus.

Faculty:

John Hovanesian, MD, FACS

President, Harvard Eye Associates
Specialist in Cornea, External Ocular Disease, Refractive and Cataract Surgery
Clinical Faculty, UCLA Jules Stein Eye Institute
Laguna Hills, CA

Disclosures: Grant/Research Support: AcuFocus, Aerie, Alcon, Allergan, Bausch + Lomb, Cord LLC, EyePoint, Glaukos, Imprimis, Johnson & Johnson Vision, Novartis, Omeros, On Point Vision, Research Insight LLC, Sight Sciences, Sun Pharma, Zeiss; Consultant: AcuFocus, Aerie, Alcon, Allergan, Apellis, Avellino Labs USA, Azura Ophthalmics, BlephEx, Bruder Healthcare, BVI, Centricity Vision, Cloudbreak Therapeutics, Cord LLC, CorneaGen, Dompe, Eyedetec, EyePoint, Glaukos, Glint Pharma, Gobiquity, GSK, Hasa Optix, Horizon Therapeutics, Hoya, Imprimis, Johnson & Johnson Vision, Kala, Novartis, Ocular Therapeutix, Oculis, Omeros, On Point Vision, Orasis, Oyster Point Pharma, Rayner, Research Insight LLC, Sensimed, SightLife, Sun Pharma, Tarsus, TearLab, Thea Pharma, Touch Ophthalmology, Trefoil Therapeutics, Vindico Medical Education, Visus, Zeiss; Other: Alcon, Alicia Surgery Center, Allegro Ophthalmics, Allergan, Apellis, Bausch + Lomb, BlephEx, Bruder Healthcare, BVI, Cloudbreak Therapeutics, Cord LLC, CorneaGen, Crisper, Dompe, Eyedetec, EyePoint, Glaukos, Glint Pharma, Gobiquity, Guardion Health Sciences, Harvard Eye Associates, Hasa Optix, Horizon Therapeutics, Hoya, Johnson & Johnson Vision, Novartis, Ocular Therapeutix, Omeros, Orasis, Research InSight LLC, RxSight, Sight Sciences, SightLife, Slack Books, Sun Pharma, Tarsus, Tear Clear, Trefoil Therapeutics, Versant Ventures and its investments, Visionary Ventures Fund 1 and 2 and its investments, Visus, Zeiss.

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER® has identified and resolved all conflicts of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.

The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.

This podcast, including the narration, was developed by PER® editorial staff based on an online activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool.

To learn more about this topic, including information on the latest treatment strategies for patients with neurotrophic keratitis, go to https://www.gotoper.com/courses/neurotrophic-keratitis-insights-an-interactive-corneal-sensitivity-testing-workshop.

Release Date

August 30, 2025

Expiration Date

August 30, 2026

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.